Aptose Biosciences Inc., of Toronto, reported preclinical data demonstrating that CG-806, a highly potent pan-FLT3/BTK inhibitor, exerts compelling activity against acute myeloid leukemia (AML) cells harboring mutant forms of FLT3 and eradicates AML tumors in a murine xenograft model.